Pacific Biosciences of California, Inc. (PACB)
Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago.
Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.97, signifying a -5.74% move from its prior day's close.
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.52, marking a +2.01% move from the previous day.
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
